Key statistics
As of last trade Jazz Pharmaceuticals PLC (J7Z:STU) traded at 118.70, -4.00% below its 52-week high of 123.65, set on Feb 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 113.00 |
---|---|
High | 119.15 |
Low | 113.00 |
Bid | 118.85 |
Offer | 119.85 |
Previous close | 112.65 |
Average volume | 79.11 |
---|---|
Shares outstanding | 60.45m |
Free float | 58.68m |
P/E (TTM) | 17.62 |
Market cap | 7.56bn USD |
EPS (TTM) | 7.10 USD |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Press releases
- Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
- Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
- Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
- Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
- Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
- PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
- Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
- Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024
More ▼